Dayane Andriotti Otta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dayane Andriotti Otta has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Olindo Assis Martins-Filho
Fundação Oswaldo Cruz, Brasil
3 shared publications A. Camila Corsini
Diagnosis and Therapy of Infectious Diseases and Cancer Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30190 002 Brazil fiocruz.br
1 shared publicationA. P. Daniel de Miranda
Diagnosis and Therapy of Infectious Diseases and Cancer Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30190 002 Brazil fiocruz.br
1 shared publicationAlice Timponi Franca
Serviço de Pesquisa, Fundação Hemominas, Belo Horizonte, MG, Brazil
1 shared publicationAna Carolina Campi-Azevedo
Integrated Biomarker Research Group Oswaldo Cruz Foundation (FIOCRUZ) 1715 Augusto de Lima Avenue, Minas Gerais Belo Horizonte 30190 002 Brazil fiocruz.br
1 shared publicationAna Maris Carlesso
Universidade Federal do Rio Grande do Sul
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2026 (1) , 3683298
Long‐Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two‐Year Cohort Study in Brazil
This two‐year cohort study evaluated immunogenicity, safety, and reactogenicity in 1675 Brazilian healthcare workers who received CoronaVac as a primary protocol (PP) followed by heterologous boosters. All vaccines were safe, with no serious adverse events. Reactogenicity was highest for Ad26.COV2.S (62.86%) as a second booster, followed by Covishield (58.56%) and Comirnaty (42.62%); CoronaVac PP reactogenicity was 19.58%. Total anti‐S IgG levels remained high throughout, increasing after the first booster. At 9 months post‐PP, Comirnaty‐boosted individuals showed superior responses versus CoronaVac alone, regardless of prior infection. No differences were observed between one or two boosters, age groups, or sex. Initially, previously infected participants had higher anti‐S IgG (6–9 months), but this difference disappeared post‐booster. Neutralizing antibodies against Omicron BA.1 were stronger in previously infected individuals at 6–12 months. The first booster increased neutralization in both groups; the second booster further enhanced responses in infection‐naive individuals and maintained them in previously infected participants, with sustained activity up to 24 months. Participants with prior COVID‐19 showed higher levels of immunological biomarkers early on, but this gap closed after the second booster, which elevated biomarkers in both groups. Cellular response, inferred from biomarker interactions, was generally higher in infection‐naive individuals. These results underscore the importance of heterologous booster regimens in sustaining long‐term humoral and cellular immunity against COVID‐19.
- 1 January 2026
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2026 (1) , 3683298
Open AccessLong‐Term Immunogenicity, Safety, and Reactogenicity of CoronaVac and Heterologous Booster Vaccines: A Two‐Year Cohort Study in Brazil
This two‐year cohort study evaluated immunogenicity, safety, and reactogenicity in 1675 Brazilian healthcare workers who received CoronaVac as a primary protocol (PP) followed by heterologous boosters. All vaccines were safe, with no serious adverse events. Reactogenicity was highest for Ad26.COV2.S (62.86%) as a second booster, followed by Covishield (58.56%) and Comirnaty (42.62%); CoronaVac PP reactogenicity was 19.58%. Total anti‐S IgG levels remained high throughout, increasing after the first booster. At 9 months post‐PP, Comirnaty‐boosted individuals showed superior responses versus CoronaVac alone, regardless of prior infection. No differences were observed between one or two boosters, age groups, or sex. Initially, previously infected participants had higher anti‐S IgG (6–9 months), but this difference disappeared post‐booster. Neutralizing antibodies against Omicron BA.1 were stronger in previously infected individuals at 6–12 months. The first booster increased neutralization in both groups; the second booster further enhanced responses in infection‐naive individuals and maintained them in previously infected participants, with sustained activity up to 24 months. Participants with prior COVID‐19 showed higher levels of immunological biomarkers early on, but this gap closed after the second booster, which elevated biomarkers in both groups. Cellular response, inferred from biomarker interactions, was generally higher in infection‐naive individuals. These results underscore the importance of heterologous booster regimens in sustaining long‐term humoral and cellular immunity against COVID‐19.
- Open Access
- 5 December 2020
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 169-176
Association between inflammatory molecules, nitric oxide metabolites and leg ulcers in individuals with sickle cell anemia
- 5 December 2020
- Published by Elsevier in Hematology, Transfusion and Cell Therapy
- Vol. 44 (2) , 169-176
Open AccessAssociation between inflammatory molecules, nitric oxide metabolites and leg ulcers in individuals with sickle cell anemia
- Open Access
- 1 April 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (4)
Identification of Anti-Trypanosoma cruzi Lead Compounds with Putative Immunomodulatory Activity
In seeking substitutions for the current Chagas disease treatment, which has several relevant side effects, new therapeutic candidates have been extensively investigated. In this context, a balanced interaction between mediators of the host immune response seems to be a key element for therapeutic success, as a proinflammatory microenvironment modulated by interleukin-10 (IL-10) is shown to be relevant to potentiate anti- Trypanosoma cruzi drug activity. This study aimed to identify the potential immunomodulatory activities of the anti- T. cruzi K777, pyronaridine (PYR), and furazolidone (FUR) compounds in peripheral blood mononuclear cells (PBMC) from noninfected (NI) subjects and chronic Chagas disease (CD) patients. Our results showed low cytotoxicity to PBMC populations, with 50% cytotoxic concentrations (CC 50 ) of 71.0 μM (K777), 9.0 μM (PYR), and greater than 20 μM (FUR). In addition, K777 showed no impact on the exposure index (EI) of phytohemagglutinin-stimulated leukocytes (PHA), while PYR and FUR treatments induced increased EI of monocytes and T lymphocytes at late stages of apoptosis in NI subjects. Moreover, K777 induced a more prominent proinflammatory response (tumor necrosis factor alpha-positive [TNF-α + ] CD8 + /CD4 + , gamma interferon-positive [IFN-γ + ] CD4 + /CD8 + modulated by interleukin-10-positive [IL-10 + ] CD4 + T/CD8 + T) than did PYR (TNF-α + CD8 + , IL-10 + CD8 + ) and FUR (TNF-α + CD8 + , IL-10 + CD8 + ). Signature analysis of intracytoplasmic cytokines corroborated the proinflammatory/modulated (K777) and proinflammatory (PYR and FUR) profiles previously found. In conclusion, the lead compound K777 may induce beneficial changes in the immunological profile of patients presenting the chronic phase of Chagas disease and may contribute to a more effective therapy against the disease.
- 1 April 2018
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (4)
Open AccessIdentification of Anti-Trypanosoma cruzi Lead Compounds with Putative Immunomodulatory Activity
In seeking substitutions for the current Chagas disease treatment, which has several relevant side effects, new therapeutic candidates have been extensively investigated. In this context, a balanced interaction between mediators of the host immune response seems to be a key element for therapeutic success, as a proinflammatory microenvironment modulated by interleukin-10 (IL-10) is shown to be relevant to potentiate anti- Trypanosoma cruzi drug activity. This study aimed to identify the potential immunomodulatory activities of the anti- T. cruzi K777, pyronaridine (PYR), and furazolidone (FUR) compounds in peripheral blood mononuclear cells (PBMC) from noninfected (NI) subjects and chronic Chagas disease (CD) patients. Our results showed low cytotoxicity to PBMC populations, with 50% cytotoxic concentrations (CC 50 ) of 71.0 μM (K777), 9.0 μM (PYR), and greater than 20 μM (FUR). In addition, K777 showed no impact on the exposure index (EI) of phytohemagglutinin-stimulated leukocytes (PHA), while PYR and FUR treatments induced increased EI of monocytes and T lymphocytes at late stages of apoptosis in NI subjects. Moreover, K777 induced a more prominent proinflammatory response (tumor necrosis factor alpha-positive [TNF-α + ] CD8 + /CD4 + , gamma interferon-positive [IFN-γ + ] CD4 + /CD8 + modulated by interleukin-10-positive [IL-10 + ] CD4 + T/CD8 + T) than did PYR (TNF-α + CD8 + , IL-10 + CD8 + ) and FUR (TNF-α + CD8 + , IL-10 + CD8 + ). Signature analysis of intracytoplasmic cytokines corroborated the proinflammatory/modulated (K777) and proinflammatory (PYR and FUR) profiles previously found. In conclusion, the lead compound K777 may induce beneficial changes in the immunological profile of patients presenting the chronic phase of Chagas disease and may contribute to a more effective therapy against the disease.
- 25 July 2012
- Published by Springer Nature in Parasitology Research
- Vol. 111 (5) , 2017-2022
Prevalence of Acanthamoeba spp. (Sarcomastigophora: Acanthamoebidae) in wild populations of Aedes aegypti (Diptera: Culicidae)
Studies of interrelationship between microorganisms and mosquitoes are of great importance, since it can provide support for better understand related to biology, development and their control. In this way, it is known that mosquito larvae and free-living amoebae (FLA) normally occupy similar aquatic microhabitats. However, few studies have been conducted about such coexistence. For that reason, the objective of the present study was to verify the prevalence of Acanthamoeba spp. in wild populations of Aedes aegypti, as well as to characterize the genotypic lineage, and their possible pathogenicity through thermo- and osmotolerance. Amoebae were investigated in 60 pools, each containing ten larvae of A. aegypti, collected in Porto Alegre (Rio Grande do Sul, Brazil). The Acanthamoeba isolates were morphologically characterized and submitted to the polymerase chain reaction technique to confirm identification of the genus. In addition, genotype analyses as well as tests for presumptive pathogenicity in some samples were performed. Of the 60 pools examined, 54 (90 %) were positive for FLA. Of these isolates, 47 (87 %) belonged to the genus Acanthamoeba. The genotypic groups T4, T3 and T5 were identified, numbering 14 (53.8 %), ten (38.5 %) and two (7.7 %) isolates, respectively. The physiological tests performed with 14 strains showed that 12 (85.7 %) were non-pathogenic, while two (14.3 %) were considered as having low pathogenic potential. These results provide a basis for a better understanding of the interaction between these protozoan and mosquitoes in their natural habitat. This study is the first to report the isolation of Acanthamoeba spp. from wild mosquitoes.
- 25 July 2012
- Published by Springer Nature in Parasitology Research
- Vol. 111 (5) , 2017-2022
Prevalence of Acanthamoeba spp. (Sarcomastigophora: Acanthamoebidae) in wild populations of Aedes aegypti (Diptera: Culicidae)
Studies of interrelationship between microorganisms and mosquitoes are of great importance, since it can provide support for better understand related to biology, development and their control. In this way, it is known that mosquito larvae and free-living amoebae (FLA) normally occupy similar aquatic microhabitats. However, few studies have been conducted about such coexistence. For that reason, the objective of the present study was to verify the prevalence of Acanthamoeba spp. in wild populations of Aedes aegypti, as well as to characterize the genotypic lineage, and their possible pathogenicity through thermo- and osmotolerance. Amoebae were investigated in 60 pools, each containing ten larvae of A. aegypti, collected in Porto Alegre (Rio Grande do Sul, Brazil). The Acanthamoeba isolates were morphologically characterized and submitted to the polymerase chain reaction technique to confirm identification of the genus. In addition, genotype analyses as well as tests for presumptive pathogenicity in some samples were performed. Of the 60 pools examined, 54 (90 %) were positive for FLA. Of these isolates, 47 (87 %) belonged to the genus Acanthamoeba. The genotypic groups T4, T3 and T5 were identified, numbering 14 (53.8 %), ten (38.5 %) and two (7.7 %) isolates, respectively. The physiological tests performed with 14 strains showed that 12 (85.7 %) were non-pathogenic, while two (14.3 %) were considered as having low pathogenic potential. These results provide a basis for a better understanding of the interaction between these protozoan and mosquitoes in their natural habitat. This study is the first to report the isolation of Acanthamoeba spp. from wild mosquitoes.